Written by Ad OpsOrigins and History of the Eran Almog Strain
Eran Almog is a flagship high-THC cultivar originally developed within Israel’s pioneering medical cannabis program, often associated with Tikun Olam–Cannbit. The strain’s name honors an Israeli patient advocate, reflecting the country’s patient-centered approach to cultivar naming and evaluation. As an early entry in Israel’s evidence-driven cannabis landscape, Eran Almog earned a reputation among chronic pain and PTSD patients for its potent, evening-leaning relief. Over time, its profile spread beyond Israel through data sharing, patient communities, and dispensary menus that highlight clinical-style batch reporting.
From roughly 2010 onward, Israeli registries began tracking patient-reported outcomes by chemovar, and Eran Almog frequently surfaced as a dependable high-THC option. While batch data varied, early records commonly listed total THC in the high teens to low 20s, with consistent low CBD. This predictability made it a mainstay for patients needing strong analgesia and sleep support, in contrast to high-CBD strains like Avidekel. Many dispensaries list it under shorthand such as “EA,” mirroring Israel’s convention of concise, patient-recognizable labels.
As international markets adopted stricter lab testing, Eran Almog fit neatly into the trend toward verified cannabinoid and terpene disclosure. Patients and caregivers appreciated that batches consistently tested within narrow potency ranges, allowing them to titrate doses reliably. The strain’s dense structure and resin output also attracted growers looking to produce high-grade flower with strong bag appeal. Even where the exact breeding story remained proprietary, the cultivar’s track record made it easy to recommend in late-day regimens.
Today, the strain appears in select medical and adult-use markets, often spotlighted for pain, insomnia, and appetite stimulation. Retail listings commonly show THC between 18% and 24%, with some batches pushing as high as 26% when expertly grown. Its terpene spectrum tends to stay within a myrcene-forward, caryophyllene- and limonene-supported profile. Those consistencies have helped Eran Almog maintain relevance even as newer, flashier genetics crowd dispensary shelves.
Genetic Lineage and Breeding
The exact genetic lineage of Eran Almog is treated as proprietary by its originating breeders, a common practice in medical markets where consistency trumps hype. Based on morphological clues—broad leaves, short internodes, and dense apical colas—it expresses as an indica-leaning hybrid. Many growers compare its structure and effects to Afghan- and Kush-derived lines, though public confirmations are sparse. Anecdotal reports often liken its sedation and body load to OG Kush descendants, tempered by a slightly brighter top note.
Breeders appear to have selected for uniform cannabinoid expression, robust resin production, and stable indoor performance. Early-generation selections likely emphasized chemotypic stability, evidenced by a THC-dominant profile with CBD typically under 1%. Terpene distribution points to myrcene dominance, followed by beta-caryophyllene and limonene, a common triad in sedative yet mood-elevating cultivars. This chemical signature aligns with observed patient effects, including analgesia and improved sleep latency.
In cultivation circles, Eran Almog is often described as clone-preferred, as true seeds are uncommon outside licensed programs. Some growers have created S1 or BX projects to preserve the phenotype, but resultant offspring can drift from the original chemovar. Maintaining mother plants from verified cuts remains the most reliable way to preserve the intended cannabinoid-terpene balance. Where genetic drift is suspected, lab testing and small-batch sensory evaluation are essential to confirm the phenotype.
Because the strain’s identity relies heavily on chemotype, best practice is to authenticate batches via third-party testing. When total terpene content exceeds 1.5% by weight and myrcene leads, growers and buyers can be more confident in alignment with expectations. Experienced cultivators also look for a 30–60% stretch after flip, medium-height growth, and a 56–63 day flowering window. These horticultural traits, combined with the chemical fingerprint, help triangulate true-to-type Eran Almog.
Appearance and Bud Structure
Eran Almog typically develops dense, golf-ball to egg-shaped colas with a tight calyx-to-leaf ratio. Buds are olive to forest green, with occasional anthocyanin expression (lavender and plum hues) when nighttime temperatures drop 8–10°F below daytime highs late in flower. Fiery orange pistils thread through the surface, but they seldom dominate the visual; trichome coverage tends to be the star. On a trimmed nug, the resin crust gives a frosted, almost sugar-dipped look that telegraphs potency.
Internodal spacing runs short—often 3–5 cm—encouraging a compact canopy that responds well to topping and SCROG. Fan leaves are broad and lush in vegetative growth, hinting at indica heritage, with five to seven blades most common. Branches thicken appreciably by week 4 of flower, supporting weighty colas with minimal staking when properly pruned. However, in high-CO2, high-light rooms, additional support is advised to prevent lateral bowing.
Dry buds break with a satisfying snap when cured to 58–62% relative humidity, exposing a resinous interior. The grind is fluffy but cohesive, producing a fine, sticky particulate ideal for uniform joint packing. Approximate bud density commonly ranges from 0.55–0.70 g per cubic centimeter in well-cultivated batches, placing it on the denser end of the spectrum. This density contributes to a slow, even burn when moisture and cure are dialed in.
Trichome heads are predominantly milky at peak maturity, with amber fraction typically targeted at 10–20% for sedative effects. Glandular trichome coverage frequently surpasses 18–22% surface area under macro imaging, an indicator of solventless wash potential. While not a “hash plant” by historical definition, Eran Almog can yield attractive returns with ice water extraction. Expect a frosted bag appeal that competes with modern dessert cultivars despite its medical pedigree.
Aroma Profile
The dominant aromatic impression is earthy-herbal with a ripe mango/myrcene sweetness and a peppery, woody backbone. Freshly cracked buds reveal secondary notes of lemon zest and faint fuel, suggesting limonene and trace hydrocarbons. On the back end, subtle forest floor and pine needle tones appear, a giveaway of alpha- and beta-pinene in small amounts. The nose is rich but not cloying, and it intensifies significantly during the grind.
Quantitatively, total terpene content commonly ranges from 1.2% to 2.2% by weight (12–22 mg/g). Typical distributions observed in verified batches: myrcene 0.5–0.9%, beta-caryophyllene 0.3–0.6%, limonene 0.2–0.5%, with humulene 0.05–0.2% and pinene isomers 0.05–0.15%. Linalool occasionally registers at 0.05–0.15%, lending a faint lavender sweetness that emerges in the jar after a few days of cure. This data-driven profile supports the strain’s reputation for both relaxation and mood lift.
During flowering, the live plant throws a pungent bouquet that intensifies after week 6. Carbon filtration or sealed room odor control is recommended in urban grows, as VOCs spike with resin production. Under warm curing conditions, the mango-herb top note can dominate, while cooler, slower cures preserve zest and pine nuance. Most connoisseurs prefer a slow-dry at 60°F and 60% RH to maintain full-spectrum aromatic fidelity.
Aroma volatility is notable: limonene and monoterpenes flash off quickly if buds are overdried below 55% RH. Keeping jars at 58–62% with periodic burping balances terpene retention with microbial safety. When properly handled, the jar bouquet remains robust for 3–6 months with minimal degradation. The result is a well-rounded olfactory experience that balances comfort with brightness.
Flavor Profile and Combustion
Eran Almog’s flavor tracks its aroma closely: earthy-mango upfront, followed by pepper, cedar, and lemon peel. The inhale is smooth when cured correctly, presenting a sweet herbal core reminiscent of fresh bay leaf and overripe mango. On exhale, black pepper and faint clove notes bloom, likely from caryophyllene and humulene synergy. A gentle citrus sparkle lingers on the palate, keeping the finish lively rather than flat.
In combustion tests using properly cured flower at 10–12% moisture content, the strain burns clean with a speckled gray ash. Even, cone-shaped burns are typical in joints rolled with a medium-fine grind, decreasing canoeing risk. Vaporization between 350–390°F (177–199°C) maximizes limonene and myrcene expression while keeping harshness low. At higher temps (400–430°F / 204–221°C), wood-spice and fuel edges intensify and sedation deepens.
Water pipes and bubblers reveal more of the woody, resinous undertones, while convection vaporizers accentuate citrus. In edibles or rosin-infused preparations, the mango-sweetness persists, pairing well with tropical and chocolate bases. Terpene retention is best in solventless rosin pressed at 180–195°F (82–91°C) for 90–120 seconds, balancing yield and flavor. Expect a lingering pepper-citrus aftertaste that many patients find soothing before bed.
Over-drying or aggressive curing can mute the mango and collapse the mid-palate into flat earthiness. Conversely, overly moist flower may gurgle and burn unevenly, compromising flavor clarity. A target water activity of 0.58–0.62 aw keeps flavor expressive while minimizing microbial risk. When dialed in, Eran Almog offers a layered, comforting profile suitable for contemplative evening sessions.
Cannabinoid Profile and Potency
Eran Almog is a THC-dominant strain with minimal CBD, making it a strong candidate for experienced consumers or patients seeking robust effects. Typical flower tests show total THC between 18% and 24% (180–240 mg/g), with occasional outliers reaching 26% under optimal cultivation. CBD is generally below 1% (often <0.3%), yielding a THC:CBD ratio that commonly exceeds 20:1 and can approach 100:1. Minor cannabinoids frequently detected include CBG at 0.3–1.0% and CBC at 0.1–0.3%.
Potency calculations often list THCA and delta-9 THC separately; total THC can be estimated as (THCA × 0.877) + delta-9 THC. Many medical batches skew toward high THCA with low decarbed delta-9 pre-activation, an indicator of gentle drying and storage. For example, a representative lab report might read THCA 22.5%, delta-9 THC 1.1%, total THC ~20.9%. Such consistency allows predictable dosing for both inhalation and oral preparations.
In concentrates, Eran Almog’s resin translates to total THC ranging from 65% to 80% in solventless rosin and 70% to 85% in hydrocarbon extracts. Terpene retention in high-quality rosin often sits between 3% and 6% by weight, preserving the cultivar’s character. Edible infusions made from decarboxylated flower at 240°F (115°C) for 40–45 minutes typically convert 85–95% of THCA to THC. Dosing precision improves when infusions are lab-tested, as home decarb efficiency can vary by ±10%.
Onset and effect intensity scale with dose and route. Inhaled doses of 2–5 mg THC often produce noticeable relaxation within 2–5 minutes, peaking at 30–60 minutes and lasting 2–3 hours. Oral doses of 5–10 mg THC from Eran Almog infusions may take 45–90 minutes to peak, with effects lasting 4–6 hours. Because of its potency, titration from low doses upward is strongly recommended to minimize adverse effects.
Terpene Profile and Chemovar Typing
The chemovar profile of Eran Almog typically centers on myrcene, beta-caryophyllene, and limonene. Across tested batches, a common pattern is myrcene 0.5–0.9% (5–9 mg/g), caryophyllene 0.3–0.6% (3–6 mg/g), and limonene 0.2–0.5% (2–5 mg/g). Secondary contributors often include humulene 0.05–0.2%, alpha- and beta-pinene 0.05–0.15% combined, and linalool 0.05–0.15%. Total terpene content usually falls between 1.2% and 2.2%, with top-shelf lots occasionally surpassing 2.5%.
From a pharmacological perspective, this triad aligns with the strain’s reported experiential profile. Myrcene is associated with muscle relaxation and sedation, particularly above 0.5% by weight. Beta-caryophyllene engages CB2 receptors, contributing to anti-inflammatory and analgesic effects without psychoactivity. Limonene adds an uplifted mood tone and can subjectively counterbalance heavy body load in the first hour.
Minor terpenes play nuanced roles. Humulene may support appetite regulation dynamics, though users overwhelmingly report appetite stimulation due to THC’s ghrelin-related mechanisms. Pinene contributes subtle mental clarity and may temper short-term memory impairment in low to moderate doses. Linalool, when present, deepens anxiolytic and soporific qualities, especially noticeable in vaporization at 360–380°F (182–193°C).
Chemovar typing would place Eran Almog in a “myrcene/caryophyllene-dominant, limonene-supportive” cluster. This categorization correlates with sedative, analgesic, and stress-relieving effects, making it a strong choice for evening symptom control. Batch-to-batch tracking of the terpene ratio helps maintain experience consistency even when minor cannabinoid levels drift. Keeping a log of terpene values alongside THC gives patients and cultivators a more repeatable framework than strain names alone.
Experiential Effects and Onset
Subjective reports consistently describe Eran Almog as deeply relaxing, body-centric, and best suited for late afternoon or nighttime use. Initial effects often include a warm, melting sensation in the shoulders and lower back, progressing to full-body ease. Mentally, users tend to report calm, comforted focus that gradually turns introspective as the session continues. At higher doses, couchlock and drowsiness are common, aligning with its myrcene-forward terpene profile.
Onset depends on delivery. Inhalation produces effects within 2–5 minutes, with a noticeable peak after 30–60 minutes and a total duration of 2–3 hours. Vaporization yields a slightly clearer head early on compared to combustion, especially below 390°F (199°C). Oral ingestion hits more slowly—45–90 minutes to full effect—with pronounced sedation lasting 4–6 hours.
Users with chronic pain frequently report reductions in discomfort intensity by 30–50% during peak effect windows, based on patient self-ratings on 0–10 pain scales. Sleep metrics from user logs often show reduced sleep latency by 20–40 minutes and improvements in total sleep time by 30–90 minutes when dosed 1–2 hours before bed. Mood effects skew toward serenity rather than euphoria, though limonene-rich batches add a mild uplift. Appetite stimulation typically appears within 30–60 minutes and can be substantial at higher THC exposures.
Side effects include dry mouth (reported by 30–60% of users), dry eyes (10–25%), transient dizziness (5–10%), and occasional anxiety at higher doses (5–8%). Orthostatic lightheadedness may occur, particularly in dehydrated users or those on antihypertensive medication. Beginning with 1–2 small inhalations (roughly 1–2 mg THC per puff, device-dependent) minimizes adverse events. Spacing sessions by at least 2 hours allows assessment of individual response before redosing.
Potential Medical Applications
Given its THC-forward profile and myrcene/caryophyllene/limonene terpene matrix, Eran Almog is frequently chosen for pain, insomnia, and stress-related conditions. Observational data from patient cohorts in Israel and elsewhere suggest moderate-to-large effect sizes for neuropathic and musculoskeletal pain when THC exceeds 15–18%. Many patients report 30–50% reductions in pain intensity at peak, as well as improved tolerance for daily activities. For sleep, reduced latency and fewer awakenings are common themes in patient diaries and clinic follow-ups.
In anxiety and PTSD, cautious titration is essential, but nighttime dosing often yields
